Symphar

What Symphar does

Symphar Sp. z o.o. is a Polish private limited company (Sp. z o.o.) headquartered in Warsaw at ul. Koszykowa 65, with a secondary office at Aleje Jerozolimskie 98. Founded in 2003 and operating with 101-250 employees, the company provides pharmaceutical, medical, and nutritional products across five core categories: prescription drugs (RX), over-the-counter medications (OTC), dietary supplements, medical devices, and cosmetics. Symphar's stated vision is to become "a strong global partner in the specialized care sector," distributing products through pharmacy networks and healthcare institutions across both well-regulated and emerging markets, with marketing reach executed primarily through conference participation and media partnerships with leading medical specialty societies.

The company underwent a transformative consolidation in 2025, completing an absorption merger with Farmak International Sp. z o.o. effective July 1, 2025. Symphar acted as the absorbing entity, taking over the entire assets of Farmak International, and Magdalena Marzec was appointed President of the Management Board of the combined entity on the same date. Founder Simon Lucas remains associated with the company as founder and president. Symphar's GTM motion is conference-driven and specialty-focused, with documented 2025 partnerships including the European Congress of Radiology, Mayo Clinic Neurology, the Polish Diabetes Society (PTD), the Polish Medical Radiological Society, the III Polish Congress of Neurology and Psychiatry, and the Slawex 2025 pharmaceutical conference.

The business model is a horizontal pharmaceutical distribution and marketing operation: no pricing is publicly disclosed, no revenue figures are available, and no funding rounds are recorded in the source data. Customer segmentation is described at a category level — healthcare providers (hospitals, pharmacies, medical institutions) as the primary vertical, with patient/end consumers as a secondary persona — reflecting a diversified volume-based go-to-market rather than concentrated enterprise sales. No AI/ML capabilities, proprietary technology platforms, or differentiated technical architecture are evidenced in the inputs.

Name

Symphar

Legal name

Symphar Sp. z o.o.

Website

https://symphar.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Symphar Sp. z o.o. is a Warsaw-based pharmaceutical company that distributes prescription drugs, OTC medications, dietary supplements, medical devices, and cosmetics to healthcare providers and patients globally through pharmacy and healthcare institution networks, following its 2025 merger with Farmak International.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Pharmacy Logistics, Returns, Reverse Distribution & Compliance Services (CRAOAHAJ)

Keywords

• Prescription medications
• Over-the-counter medications
• Dietary supplements
• Medical devices
• Pharmaceutical distribution

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Others

Distribution channels1 record

Marketing channels3 records

Core offering

Symphar is a Polish pharmaceutical manufacturer and distributor that develops, produces, and markets prescription (RX) medications, over-the-counter (OTC) drugs, dietary supplements, medical devices, and cosmetics. The company delivers these products through pharmacy networks, healthcare institutions, and pharmaceutical wholesalers, serving both well-regulated and emerging markets with a portfolio anchored in the specialized care segment.

Product overview

Farmak International Sp. z o.o. is a pharmaceutical company that offers a diversified portfolio of healthcare products including prescription drugs (Leki RX), over-the-counter medications (Leki OTC), dietary supplements (Suplementy diety), medical devices (Wyroby medyczne), and cosmetics (Kosmetyki). The company is currently undergoing a merger with Symphar Sp. z o.o., with the connection planned through an asset takeover by Symphar.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription medications (RX) Prescription pharmaceutical products developed and manufactured by Symphar for distribution through pharmacies, hospitals, and healthcare institutions in regulated and emerging markets.
• Over-the-counter (OTC) medications Non-prescription pharmaceutical products sold directly through retail pharmacies as part of Symphar's commercial portfolio.
• Dietary supplements Nutritional and dietary supplements distributed through pharmacy networks and healthcare providers as part of Symphar's broader health product range.
• Medical devices Medical devices produced and distributed through healthcare institutions and pharmacy networks to support patient care alongside Symphar's pharmaceutical portfolio.
• Cosmetics Cosmetic products distributed through pharmacy and healthcare channels, complementing Symphar's pharmaceutical and health-focused offerings.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and flagship.

• Mayo Clinic NeurologycoreGTM or Marketing Partner · 28 June 2025Farmak International participated as a partner in the international Mayo Clinic Neurology conference held in Katowice, Poland
• Slawex 2025coreGTM or Marketing Partner · 8 June 2025Farmak International participated as a partner in the Ogólnopolska Konferencja Farmaceutyczna Slawex 2025 (Polish Pharmaceutical Conference)
• Polish Medical Radiological SocietycoreGTM or Marketing Partner · 1 June 2025Farmak International participated as a partner in the 44th Congress of the Polish Medical Radiological Society held in Poznań
• Polish Diabetes Society (PTD)coreGTM or Marketing Partner · 11 May 2025Farmak International participated as a partner in the XXVI Scientific Congress of the Polish Diabetes Society
• Kontrowersje w psychiatrii / Neurologia 2025coreGTM or Marketing Partner · 13 April 2025Farmak International participated as a partner in the XVII Scientific Conference 'Controversies in Psychiatry' and 'Neurology 2025' in Kraków
• Symphar Sp. z o.o.flagshipStrategic or Co-development Partner · 25 March 2025Merger announced between Farmak International Sp. z o.o. and Symphar Sp. z o.o. The combination occurred through Symphar Sp. z o.o. taking over all assets of Farmak International Sp. z o.o. This merger integrates the two pharmaceutical companies under unified ownership.
• III Polish Congress of Neurology and PsychiatrycoreGTM or Marketing Partner · 21 March 2025Farmak International participated as a partner in the III Polish Congress of Neurology and Psychiatry held in Warsaw 2025
• European Congress of Radiology (ECR) 2025coreGTM or Marketing Partner · 4 March 2025Farmak International team participated in the European Congress of Radiology 2025, one of the largest medical imaging events in the world held February 26 - March 2, 2025

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• NEUCA: Polish group combining pharmaceutical wholesale, retail pharmacy, and clinical services — directly comparable Polish pharma distributor with adjacent services, similar customer base of pharmacies and healthcare providers, and overlapping product categories (RX, OTC, supplements).
• Pelion Healthcare Group: Lithuania-headquartered Central and Eastern European pharmaceutical wholesaler and retailer, with wholesale distribution across CEE markets — comparable to Symphar in business model, product breadth, and CEE-focused geographic footprint.
• PGF (Polska Grupa Farmaceutyczna): Polish pharmaceutical wholesaler distributing RX, OTC, and pharmacy-related products to pharmacies and healthcare institutions across Poland — directly comparable to Symphar/Farmak International's core wholesale distribution model in the same geography.

Regional players

• Mediq: European distributor of medical devices, pharmaceuticals, and healthcare products, focused on healthcare providers and patients — overlaps with Symphar's medical-device and pharmaceutical distribution activities, but with a stronger Western European footprint.
• Tamro (Phoenix Group): Nordic pharmaceutical wholesaler distributing RX, OTC, and health products to pharmacies — comparable business model to Symphar but primarily serving Finland and the Baltics rather than Poland/CEE.

Broad incumbents

• McKesson: Global pharmaceutical distributor and healthcare services company with extensive wholesale operations — represents the scale end of pharmaceutical distribution against which Symphar's regional CEE model must compete on service and relationships.
• Phoenix Group: European pharmaceutical distribution group headquartered in Germany, operating across 29 countries with integrated wholesale and retail pharmacy operations — overlaps Symphar's pharmaceutical distribution model at a far larger European scale.
• Alliance Healthcare (Walgreens Boots Alliance): Major European pharmaceutical wholesaler serving pharmacies across multiple European countries, owned by Walgreens Boots Alliance — directly comparable pharma-wholesale business model but at significantly larger scale and broader geographic reach than Symphar.
• Cencora (formerly AmerisourceBergen): Global pharmaceutical solutions company providing distribution and related services across North America and Europe — competes at the high end of pharmaceutical distribution and establishes the broader competitive context for Symphar's wholesale business.

Others

• Farmak (Ukraine): Major Ukrainian pharmaceutical manufacturer and the parent of Farmak International (now merged into Symphar) — thematically related as a manufacturer feeding CEE distribution, but distinct as a producer rather than a distributor comparable to Symphar.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symphar